NattoPharma ASA, in collaboration with Complementary Medicines Group (CMG) Australia, has successfully entered the Australian and New Zealand markets, including supplying major sponsor brands.

This collaboration has resulted in exciting developments. First, Blackmores, Australia’s leading natural health brand, will utilize NattoPharma’s MenaQ7 Vitamin K2 in a soon-to-be released product that will be sold both online and through brick-and-mortar stores across Australia. BioCeuticals, supplier of high-quality practitioner-specific nutritional and therapeutic supplements, has also signed on to use its MenaQ7 Vitamin K2 in an upcoming product.

In addition, another new product concept has already been released: Essential Nutrition Vitamin K2, a standalone bone health product featuring NattoPharma’s MenaQ7 Vitamin K2 as MK-7, the only clinically validated and patented vitamin K2 as MK-7. The product is currently being sold online at www.essentialnutrition.net.au, and will in November 2014 be sold exclusively through Go Vita, a 150-store retail natural products chain.

“Bone health is a serious concern, and the introduction of MenaQ7 Vitamin K2 to the Australian and New Zealand markets has been significant. We are energized,” said Craig Fallshaw, CMG Founder. “It is so validating to bring the only clinically validated, patented vitamin K2 as MK-7 to these markets.”

In close collaboration with NattoPharma ASA, CMG has leveraged relationships to bring the current product offering to market, as well as other opportunities for future products, and increase awareness of this important bone health ingredient. 

“We are very pleased to make significant progress in Australia and New Zealand introducing our proprietary, patented, and clinically proven MenaQ7 Vitamin K2 as MK-7,” said Hogne Vik, CEO of NattoPharma ASA. “We look forward to a long and successful relationship with CMG and its partner groups.”